Any current/future new fundraising through debt or equity?

No immediate plans for new fundraising through equity or debt as the company currently has sufficient cash flows. Past preferential allotment was postponed to seek higher prices; discussions with investors are ongoing but no final decisions made. The company is open to taking term loans for buildings or other needs if required but has not yet signed any agreements. CAPEX for the current year (around Rs.35-40 crores) and investments in Medical Devices (around Rs.20 crores) will be funded through internal accruals. Working capital requirements are increasing, and the company may consider local a

Any current/future capex/capital investment/strategic investment?

Total CAPEX requirement is Rs.178 crores over three years; Rs.35-40 crores expected to be spent in the current year. API segment investment of Rs.35-40 crores planned from internal accruals. Medical Devices segment to receive around Rs.20 crores investment, also from internal accruals. Potential backward integration for intermediate chemicals currently imported from China. Additional investment may be needed for new API plant building and machinery; higher CAPEX expected next financial year. Open to term loans if required for buildings or working capital but currently relying on internal accru

Future growth expectations in sales/revenue/volumes?

The company achieved a 50% revenue growth in Q1 FY22, a phenomenal increase from previous quarters. Dr. Morepen portfolio is expected to grow to around Rs.1,000 crores in the next two years, indicating strong growth in OTC and medical devices. Diagnostics division sales grew 189% this quarter, with an increasing share of the company’s revenue; the division is expected to remain a key growth driver. API business growth is steady at 17% with plans to focus on new molecules and products linked to a $40 billion market with expiring patents. Medical Devices segment expanding capacity and ad

Future growth expectations in earnings/operating earnings/profits/EPS?

Q1 FY22 showed a remarkable 50% revenue growth and 63% EBITDA increase, signaling strong momentum. Profit before tax increased by 97%, profit after tax by 57%, and EPS is Rs.0.68 for the quarter, annualized to around Rs.2.40. EBITDA margins improved from 10.8% to 11.7%, expected to inch more positive with stable margins across segments. API segment growth driven by new molecule capacity and ANDA filings targeting a $40 billion market over next two years. Dr. Morepen OTC portfolio expected to grow to Rs.1,000 crores in next 1-2 years, potentially leading to separate subsidiary and IPO.

Morepen Laboratories LtdQ1 FY22Pharmaceuticals & Biotechnology

Morepen Laboratories Ltd Q1 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹119P/E: 56.2Market Cap: ₹6.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company achieved a 50% revenue growth in Q1 FY22, a phenomenal increase from previous quarters.
Dr. Morepen portfolio is expected to grow to around Rs.1,000 crores in the next two years, indicating strong growth in OTC and medical devices.
Diagnostics division sales grew 189% this quarter, with an increasing share of the company’s revenue; the division is expected to remain a key growth driver.
API business growth is steady at 17% with plans to focus on new molecules and products linked to a $40 billion market with expiring patents.
Medical Devices segment expanding capacity and adding new products, projected to keep growing along with Finished Dosage business recovery (30% growth).
COVID-driven demand for diagnostic devices may normalize but heightened health awareness is expected to sustain higher usage and sales long-term.
Overall company poised for continued robust growth fueled by expansion in diagnostics, formulations, and new product launches.

Margin guidance

Category 3

Q1 FY22 showed a remarkable 50% revenue growth and 63% EBITDA increase, signaling strong momentum.
Profit before tax increased by 97%, profit after tax by 57%, and EPS is Rs.0.68 for the quarter, annualized to around Rs.2.40.
EBITDA margins improved from 10.8% to 11.7%, expected to inch more positive with stable margins across segments.
API segment growth driven by new molecule capacity and ANDA filings targeting a $40 billion market over next two years.
Dr. Morepen OTC portfolio expected to grow to Rs.1,000 crores in next 1-2 years, potentially leading to separate subsidiary and IPO.
Medical Devices segment demonstrating strong growth and capacity expansion, supported by COVID-driven demand.
CAPEX of Rs.35-40 crores planned this year to support expansion, mainly via internal accruals, with potential term loans as needed.
Overall outlook remains positive with management confident of sustained growth and profitability improvements.

See what Morepen Laboratories Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

No immediate plans for new fundraising through equity or debt as the company currently has sufficient cash flows.
Past preferential allotment was postponed to seek higher prices; discussions with investors are ongoing but no final decisions made.
The company is open to taking term loans for buildings or other needs if required but has not yet signed any agreements.
CAPEX for the current year (around Rs.35-40 crores) and investments in Medical Devices (around Rs.20 crores) will be funded through internal accruals.
Working capital requirements are increasing, and the company may consider local arrangements for working capital financing if needed.
Management is keen on wealth creation for all shareholders and cautious about undervaluation in any fundraising.

Order book

- The transcript does not explicitly mention the current or expected order book or pending orders for Morepen Laboratories Limited. - For the Sputnik vaccine, six trial batches have been sent for testing, with commercial production expected to start within 4-6 weeks pending approval. - The company has a capacity to fill up to 250 million doses per annum for Sputnik, potentially increasing to 500 million doses based on bulk supply and demand. - Discussions on capacity expansion in API and Medical Devices suggest growing demand and internal accrual investments, but no specific order backlog figures are provided. - The company’s diagnostic devices division sales have grown significantly, indicating strong demand, but no order book details are disclosed. No direct information on a specific order book or pending orders is available in the transcript.

See what Morepen Laboratories Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Total CAPEX requirement is Rs.178 crores over three years; Rs.35-40 crores expected to be spent in the current year.
API segment investment of Rs.35-40 crores planned from internal accruals.
Medical Devices segment to receive around Rs.20 crores investment, also from internal accruals.
Potential backward integration for intermediate chemicals currently imported from China.
Additional investment may be needed for new API plant building and machinery; higher CAPEX expected next financial year.
Open to term loans if required for buildings or working capital but currently relying on internal accruals.
No major investments planned yet for Sputnik vaccine bulk production; only working capital might be needed.
Strategic focus on biosimilars and new biological products with expansions aligning to these areas.

Track Morepen Laboratories Ltd — get its next earnings analysis in your feed

How does Morepen Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisMorepen Laboratories Ltd

Rev 2Mar 3

See where Morepen Laboratories Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Morepen Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Morepen Laboratories Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Morepen Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
FDC Ltd (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →